Considering that ICB therapy commonly leads to immune adverse events like dermatitis, colitis, and pneumonitis (28), understanding how TSLP and other alarmin cytokines regulate immune response to ICB therapy at barrier sites will have major therapeutic implications. This evidence concerns the gene TSLP and dermatitis.